BOSTON SCIENTIFIC CORP
Customers
2
2 federal agencies
Suppliers
1
1 disclosed
Federal obligations
$5.3M
FY2027 · USAspending.gov
Latest period
Dec 31, 2025
10-K filed 2026-02-23
Suppliers 1
Companies that disclose BSX as a major customer, as a share of their own revenue. 1 active, 0 lapsed.
| Company | % of their revenue | Est. $ from BSX | Period | Trend | Status | Source |
|---|---|---|---|---|---|---|
| ITGR Integer Holdings Corp |
Named | — | FY 2025-12-31 | — | Active | 10-K 2026-02-23 |
During 2025, three of our customers, Abbott Laboratories, Boston Scientific and Medtronic were each in excess of 10% of total sales and collectively accounted for 49% of our total sales. | ||||||
Federal contracts 2
Agencies that awarded contracts to this company, from USAspending.gov. Dollars are obligated amounts as reported, not estimates; $18.6M in the latest fiscal year shown per agency.
| Agency | Obligated | Fiscal year | Awards | Trend | Largest award |
|---|---|---|---|---|---|
| Department of Defense
Department of the Army |
$13.3M | FY 2026 | 1,292 | $17.7M → $14.8M → $19.4M → $13.3M | W81K0025PA252 |
TRANSARTERIAL RADIOEMBOLIZATION USING YTTRIUM-90 MICROSPHERES IS A THERAPEUTIC OPTION FOR PATIENTS WITH INTERMEDIATE-OR ADVANCED-STAGE HEPATOCELLULAR CARCINOMA, INCLUDING THOSE WITH RECURRENT OR INOPERABLE HEPATOCELLULAR CARCINOMA. | |||||
| Department of Veterans Affairs
Department of Veterans Affairs |
$5.3M | FY 2027 | 13 | $14.4M → $8.8M → $10.6M → $8.1M → $5.3M | 36C26227N0072 |
THERASPHERE Y90 | |||||
Named as competitors
Companies this filer names as competitors.
Alerts are coming
Get an email when BSX's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.